La pasión de EE. UU. por las pastillas para dormir quizá esté menguando
MIÉRCOLES, 24 de agosto de 2022 (HealthDay News) — Menos estadounidenses recurren a los somníferos para luchar contra el insomnio.Tras un aumento dramático en las recetas para medicamentos como Ambien, la tendencia se ha reducido, según un nuevo estu…
Learn MoreRates of Severe COVID-19 Lower With Nirmatrelvir in ≥65s
THURSDAY, Aug. 25, 2022 (HealthDay News) — For adults aged 65 years or older, nirmatrelvir is associated with reduced rates of hospitalization and death due to COVID-19, according to a study published online Aug. 24 in the New England Journal of Me…
Learn MoreOlokizumab Tops Placebo for RA Patients Receiving Methotrexate
THURSDAY, Aug. 25, 2022 (HealthDay News) — Olokizumab is superior to placebo and noninferior to adalimumab in patients with rheumatoid arthritis receiving maintenance methotrexate, according to a study published in the Aug. 25 issue of the New Englan…
Learn MoreACOG Develops Consensus on Medical Menstrual Suppression
WEDNESDAY, Aug. 24, 2022 (HealthDay News) — In a new clinical consensus document, the American College of Obstetrics and Gynecologists offers guidance regarding the role of hormonal medications for menstrual suppression.
Oluyemisi Adeyemi-Fowode, M…
Learn MoreAmerica’s Love Affair With Sleeping Pills May Be Waning
WEDNESDAY, Aug. 24, 2022 (HealthDay News) — Fewer Americans are turning to sleep medications to fight insomnia.After a dramatic rise in prescriptions for drugs like Ambien, the trend has ebbed, according to a new study, and fewer doctors are prescrib…
Learn MoreMuchos de los que más necesitan el antídoto para una sobredosis de opioides no pueden permitírselo
LUNES, 22 de agosto de 2022 (HealthDay News) — La naloxona es un antídoto para la sobredosis de opioides que salva vidas, pero quizá su precio sea demasiado alto para los más vulnerables a una muerte relacionada con los opioides, encuentra un estudio…
Learn MoreOut-of-Pocket Costs for Naloxone Up for Uninsured Patients
TUESDAY, Aug. 23, 2022 (HealthDay News) — The out-of-pocket (OOP) cost for naloxone has grown and poses a substantial barrier to access for uninsured patients, according to a study published online Aug. 19 in JAMA Health Forum.
Evan D. Peet, Ph.D…
Learn MoreMany Who Need Opioid OD Antidote the Most Can’t Afford It
MONDAY, Aug. 22, 2022 (HealthDay News) — Naloxone is a lifesaving antidote to an opioid overdose, but it may be priced too high for those most vulnerable to opioid-related death, a new study finds.Between 2014 and 2018, naloxone costs rose 500% for t…
Learn MoreLa ivermectina y Luvox fracasan como tratamientos para la COVID-19
JUEVES, 18 de agosto de 2022 (HealthDay News) — Dos medicamentos que se anunciaron como tratamientos para la COVID-19, la ivermectina y la fluvoxamina, no hacen nada para mejorar los niveles de oxígeno de los pacientes ni mantenerlos fuera del hospit…
Learn MoreMetformin, Ivermectin, Fluvoxamine Do Not Prevent Severe COVID-19
FRIDAY, Aug. 19, 2022 (HealthDay News) — For patients with COVID-19 infection, metformin, ivermectin, and fluvoxamine do not prevent the occurrence of hypoxemia, an emergency department visit, hospitalization, or death, according to a study publish…
Learn More